Natural killer cell therapy for cancer: Delivering on a promise

Transfusion

Volumn 53, Issue 2, 2013, Pages 245-248

  Shook, David R ^a,b   Leung, Wing ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANAMNESIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BLOOD DONOR; CANCER IMMUNOTHERAPY; CANCER RISK; CELL ENGINEERING; CELL KILLING; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; DENDRITIC CELL; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMOLYSIS; HUMAN; LYMPHOMA; MONOCYTE; MYELOMA; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; REVIEW; T LYMPHOCYTE; TUMOR CELL;

GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; NEOPLASMS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84873454381     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12091     Document Type: Review

References (40)

1. Downing JR, Wilson RK, Zhang J, Mardis ER, Pui CH, Ding L, Ley TJ, Evans WE,. The pediatric cancer genome project. Nat Genet 2012; 44: 619-622.
2. Leung W,. Immunotherapy in acute leukemia. Semin Hematol 2009; 46: 89-99.
3. Waldmann TA,. Immunotherapy: past, present and future. Nat Med 2003; 9: 269-277.
4. Yokoyama WM,. Mistaken notions about natural killer cells. Nat Immunol 2008; 9: 481-485.
5. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K,. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000; 356: 1795-1799.
6. Kolb HJ,. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008; 112: 4371-4383.
7. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, Confer DL, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367: 1487-1496.
8. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A,. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
9. Olson JA, Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS,. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood 2010; 115: 4293-4301.
10. Valiante NM, Parham P,. Natural killer cells, HLA class I molecules, and marrow transplantation. Biol Blood Marrow Transplant 1997; 3: 229-235.
11. Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, Niethammer D, Handgretinger R,. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004; 172: 644-650.
12. Leung W, Iyengar R, Triplett B, Turner V, Behm FG, Holladay MS, Houston J, Handgretinger R,. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 2005; 174: 6540-6545.
13. Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, Gallagher MM, Malkki M, Petersdorf E, Dupont B, Hsu KC,. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 2012; 367: 805-816.
14. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, Marsh SG, Geraghty D, Spellman S, Haagenson MD, Ladner M, Trachtenberg E, Parham P, Miller JS,. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010; 116: 2411-2419.
15. Leung W, Handgretinger R, Iyengar R, Turner V, Holladay MS, Hale GA,. Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma. Br J Cancer 2007; 97: 539-542.
16. Venstrom JM, Zheng J, Noor N, Danis KE, Yeh AW, Cheung IY, Dupont B, O'Reilly RJ, Cheung NK, Hsu KC,. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res 2009; 15: 7330-7334.
17. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S,. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331: 44-49.
18. Cooper MA, Colonna M, Yokoyama WM,. Hidden talents of natural killers: NK cells in innate and adaptive immunity. EMBO Rep 2009; 10: 1103-1110.
19. Caligiuri MA,. Human natural killer cells. Blood 2008; 112: 461-469.
20. Leung W,. Use of NK cell activity in cure by transplant. Br J Haematol 2011; 155: 14-29.
21. Orange JS,. Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol 2008; 8: 713-725.
22. Smyth MJ, Hayakawa Y, Takeda K, Yagita H,. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002; 2: 850-861.
23. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB,. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-3057.
24. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, Pui CH, Leung W,. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010; 28: 955-959.
25. Curti A, Ruggeri L, D'Addio A, Bontadini A, Dan E, Motta MR, Trabanelli S, Giudice V, Urbani E, Martinelli G, Paolini S, Fruet F, Isidori A, Parisi S, Bandini G, Baccarani M, Velardi A, Lemoli RM,. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 2011; 118: 3273-3279.
26. Koepsell SA, Miller JS, McKenna DH Jr,. Natural killer cells: a review of manufacturing and clinical utility. Transfusion 2013; 53: 404-410.
27. Becknell B, Caligiuri MA,. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 2005; 86: 209-239.
28. Kalbasi A, Shrimali RK, Chinnasamy D, Rosenberg SA,. Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein. J Immunother 2010; 33: 672-683.
29. Shook DR, Campana D,. Natural killer cell engineering for cellular therapy of cancer. Tissue Antigens 2011; 78: 409-415.
30. Chan WK, Kung Sutherland M, Li Y, Zalevsky J, Schell S, Leung W,. Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands. Clin Cancer Res 2012; 18: 6296-6305.
31. Bari R, Bell T, Leung WH, Vong QP, Chan WK, Das Gupta N, Holladay M, Rooney B, Leung W,. Significant functional heterogeneity among KIR2DL1 alleles and a pivotal role of arginine 245. Blood 2009; 114: 5182-5190.
32. Bari R, Leung M, Turner VE, Embrey C, Rooney B, Holladay M, Leung W,. Molecular determinant-based typing of KIR alleles and KIR ligands. Clin Immunol 2011; 138: 274-281.
33. Lapteva N, Durett AG, Sun J, Rollins LA, Huye LL, Fang J, Dandekar V, Mei Z, Jackson K, Vera J, Ando J, Ngo MC, Coustan-Smith E, Campana D, Szmania S, Garg T, Moreno-Bost A, Vanrhee F, Gee AP, Rooney CM,. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy 2012; 14: 1131-1143.
34. Koepsell SA, Kadidlo DM, Fautsch S, McCullough J, Klingemann H, Wagner JE, Miller JS, McKenna DH Jr,. Successful "in-flight" activation of natural killer cells during long-distance shipping. Transfusion 2013; 53: 398-403.
35. McKenna DH Jr, Sumstad D, Bostrom N, Kadidlo DM, Fautsch S, McNearney S, Dewaard R, McGlave PB, Weisdorf DJ, Wagner JE, McCullough J, Miller JS,. Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion 2007; 47: 520-528.
36. Klingemann H, Grodman C, Cutler E, Duque M, Kadidlo D, Klein AK, Sprague KA, Miller KB, Comenzo RL, Kewalramani T, Yu N, Van Etten RA, McKenna DH,. Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions. Transfusion 2013; 53: 412-418.
37. Perez-Martinez A, Iyengar R, Gan K, Chotsampancharoen T, Rooney B, Holladay M, Ramirez M, Leung W,. Blood dendritic cells suppress NK cell function and increase the risk of leukemia relapse after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011; 17: 598-607.
38. Rajasekar R, Lakshmi KM, George B, Viswabandya A, Thirugnanam R, Abraham A, Chandy M, Srivastava A, Mathews V,. Dendritic cell count in the graft predicts relapse in patients with hematologic malignancies undergoing an HLA-matched related allogeneic peripheral blood stem cell transplant. Biol Blood Marrow Transplant 2010; 16: 854-860.
39. Skeate R, Singh C, Cooley S, Geller M, Northouse J, Welbig J, Slungaard A, Miller J, McKenna D,. Hemolytic anemia due to passenger lymphocyte syndrome in solid malignancy patients treated with allogeneic natural killer cell products. Transfusion 2013; 53: 419-423.
40. Iyengar R, Handgretinger R, Babarin-Dorner A, Leimig T, Otto M, Geiger TL, Holladay MS, Houston J, Leung W,. Purification of human natural killer cells using a clinical-scale immunomagnetic method. Cytotherapy 2003; 5: 479-484.